Filters








731 Hits in 1.9 sec

Efficacy and Cost of High-Frequency IGRT in Elderly Stage III Non-Small-Cell Lung Cancer Patients [article]

Samuel P Heilbroner, Eric P Xanthopoulos, Donna Buono, Daniel Carrier, Ben Y Durkee, Michael Corradetti, Tony JC Wang, Alfred I Neugut, Dawn L Hershman, Simon K Cheng
2020 medRxiv   pre-print
High-frequency image-guided radiotherapy (hfIGRT) is ubiquitous but its benefits are unproven. We examined the cost effectiveness of hfIGRT in stage III non-small-cell lung cancer (NSCLC). Methods: We selected stage III NSCLC patients >= 66 years old who received definitive radiation therapy from the Surveillance, Epidemiology, and End-Results-Medicare database. Patients were stratified by use of hfIGRT using Medicare claims. Predictors for hfIGRT were calculated using a logistic model. The
more » ... ct of hfIGRT on lung toxicity free survival (LTFS), esophageal toxicity free survival (ETFS), cancer-specific survival (CSS), overall survival (OS), and cost of treatment was calculated using Cox regressions, propensity score matching, and bootstrap methods. Results: Of the 4,430 patients in our cohort, 963 (22%) received hfIGRT and 3,468 (78%) did not. By 2011, 49% of patients were receiving hfIGRT. Predictors of hfIGRT use included treatment with intensity-modulated radiotherapy (IMRT) (OR = 7.5, p < 0.01), recent diagnosis (OR = 51 in 2011 versus 2006, p < 0.01), and residence in regions where the Medicare intermediary allowed IMRT (OR = 1.50, p < 0.01). hfIGRT had no impact on LTFS (HR 0.97; 95% CI 0.86 - 1.09), ETFS (HR 1.05; 95% CI 0.93 - 1.18), CSS (HR 0.94; 95% CI 0.84 - 1.04), or OS (HR 0.95; 95% CI 0.87 - 1.04). Mean radiotherapy and total medical costs six months after diagnosis were $17,330 versus $15,024 (p < 0.01) and $71,569 versus $69,693 (p = 0.49), respectively. Conclusion: hfIGRT did not affect clinical outcomes in elderly patients with stage III NSCLC but did increase radiation cost.
doi:10.1101/2020.12.01.20241794 fatcat:2nby356zdbb7jfo3goub7vvr5e

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach

Samuel Peter Heilbroner, Reed Few, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus, Tomas G Neilan
2021 Journal for ImmunoTherapy of Cancer  
Downloaded from Heilbroner SP, et al. J Immunother Cancer 2021;9:e002545. doi:10.1136/jitc-2021-002545Open access  ... 
doi:10.1136/jitc-2021-002545 pmid:34607896 pmcid:PMC8491414 fatcat:d5a3dtfobrb27gvuxytqyochm4

Impact of Discoordinated Care on Healthcare Utilization and Survival in Stage IV Non-Small Cell Lung Cancer Patients [article]

Samuel P Heilbroner, Eric P Xanthopoulos, Mark A Hoffman, Donna Buono, Ben Y Durkee, Michael Corradetti, Tony JC Wang, Jason D Wright, Alfred I Neugut, Dawn L Hershman, Nicholas C Rohs, Simon K Cheng
2021 medRxiv   pre-print
Cancer patients' treatment is often dispersed across multiple physician communities that may not exchange information. We measured the association between this type of discoordinated care and healthcare utilization, cost, and mortality in stage IV non-small cell lung cancer (NSCLC). Methods: Stage IV NSCLC patients ≥65 years were identified from the Surveillance, Epidemiology, and End Results database attached to Medicare claims. A discoordinated care subgroup was selected using a novel index
more » ... at approximated how many physician communities each patient encountered. Communities were defined by (1) using claims data to create a nationwide social network of healthcare providers and then (2) dividing that network into communities using cluster label propagation. Associations between discoordinated care and overall survival (OS), cancer-specific survival (CSS), hospitalizations, the burden of diagnostic imaging, and cost were assessed. Results: Of the 11,417 patients in our cohort, 5,855 received discoordinated care. Discoordination was associated with younger age, higher socioeconomic status, higher physician density, and lack of a home health aide. Discoordinated care was associated with improved OS and CSS (HR = 0.92, 95% CI 0.88 - 0.95 for OS). However, discoordinated patients also received 32% more MRIs (p = 0.007) and paid $494.02 more for imaging (p = 0.004). There was no association with other kinds of imaging, rates of hospitalization, or other healthcare costs, including total cost. Conclusions: Discoordinated care was associated with additional MRIs, but also improved survival. The reason is unclear, but discoordinated patients may be seeking the best care at the expense of continuity.
doi:10.1101/2020.12.28.20248904 fatcat:immdkspelvbwxgef6b4iu2v73i

Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease

David Andrew Bender, Samuel P Heilbroner, Tony J C Wang, Catherine A Shu, Brigham Hyde, Catherine Spina, Simon K Cheng
2020 Journal for ImmunoTherapy of Cancer  
BackgroundImmune checkpoint inhibitors (ICIs) are important new therapeutic options for the treatment of malignancy. Existing data on the relative safety of ICI treatment in patients with pre-existing autoimmune disease (AID) are limited.MethodsIn this retrospective study utilizing an oncology medical claims database, we determined the rates of treatment with immunosuppressive agents and hospitalization within 180 days of treatment with ICIs (pembrolizumab, nivolumab, and ipilimumab) in
more » ... both with and without AID. Patients had diagnoses of either malignant melanoma or lung cancer. Immunosuppressive agents evaluated included oral prednisone and intravenous methylprednisolone.Results124 cancer patients with AID and 1896 cancer patients without AID met inclusion criteria for oral prednisone analysis, while 284 patients with AID and 3230 patients without AID met inclusion criteria for all other analyzes. Following treatment with PD-1 inhibitors, rates of treatment with both oral prednisone and intravenous methylprednisolone within 180 days of ICI treatment were significantly increased in the AID group relative to the control group (oral prednisone: 16.7% treatment in AID vs 8.3% in non-AID, p=0.0048; intravenous methylprednisolone: 8.4% treatment in AID vs 3.7% in non-AID, p=0.0012). Rates of hospitalization were significantly increased in melanoma patients with AID relative to melanoma patients without AID following treatment with PD-1 inhibitors (24.1% in AID vs 5.8% in non-AID, p<0.0001).ConclusionCancer patients with AID have higher rates of hospitalization and treatment with immunosuppressive agents following treatment with ICI therapy compared with patients with no AID. This suggests that patients with AID may have increased toxicity risk while being treated with checkpoint inhibitor therapy. Further prospective clinical trials are needed to determine safety.
doi:10.1136/jitc-2020-001627 pmid:33303578 fatcat:y26xbwwmuzba5c5miweublfxba

Rhyacian-Orosirian tectonic history of the Juiz de Fora Complex: Evidence for an Archean crustal reservoir within an island-arc system

Rasec Almeida, Vitalino Elizeu, Henrique Bruno, Samuel Moreira Bersan, Lucas Eduardo de Abreu Barbosa Araujo, Ivo Dussin, Claudio de Morisson Valeriano, Carla Neto, Monica Heilbron
2021 Geoscience Frontiers  
., 2004; Heilbron et al., 2017) .  ...  , 2000; Heilbron et al., 2010) .  ... 
doi:10.1016/j.gsf.2021.101292 fatcat:n77p6sxrujhlfc46bgkygqd7ua

Efficacy and cost of high-frequency IGRT in elderly stage III non-small-cell lung cancer patients

Samuel P. Heilbroner, Eric P. Xanthopoulos, Donna Buono, Daniel Carrier, Ben Y. Durkee, Michael Corradetti, Tony J. C. Wang, Alfred I. Neugut, Dawn L. Hershman, Simon K. Cheng, Jianxin Xue
2021 PLoS ONE  
High-frequency image-guided radiotherapy (hfIGRT) is ubiquitous but its benefits are unproven. We examined the cost effectiveness of hfIGRT in stage III non-small-cell lung cancer (NSCLC). Methods We selected stage III NSCLC patients ≥66 years old who received definitive radiation therapy from the Surveillance, Epidemiology, and End-Results-Medicare database. Patients were stratified by use of hfIGRT using Medicare claims. Predictors for hfIGRT were calculated using a logistic model. The impact
more » ... of hfIGRT on lung toxicity free survival (LTFS), esophageal toxicity free survival (ETFS), cancer-specific survival (CSS), overall survival (OS), and cost of treatment was calculated using Cox regressions, propensity score matching, and bootstrap methods. Results Of the 4,430 patients in our cohort, 963 (22%) received hfIGRT and 3,468 (78%) did not. By 2011, 49% of patients were receiving hfIGRT. Predictors of hfIGRT use included treatment with intensity-modulated radiotherapy (IMRT) (OR = 7.5, p < 0.01), recent diagnosis (OR = 51 in 2011 versus 2006, p < 0.01), and residence in regions where the Medicare intermediary allowed IMRT (OR = 1.50, p < 0.01). hfIGRT had no impact on LTFS (HR 0.97; 95% CI 0.86–1.09), ETFS (HR 1.05; 95% CI 0.93–1.18), CSS (HR 0.94; 95% CI 0.84–1.04), or OS (HR 0.95; 95% CI 0.87–1.04). Mean radiotherapy and total medical costs six months after diagnosis were $17,330 versus $15,024 (p < 0.01) and $71,569 versus $69,693 (p = 0.49), respectively. Conclusion hfIGRT did not affect clinical outcomes in elderly patients with stage III NSCLC but did increase radiation cost. hfIGRT deserves further scrutiny through a randomized controlled trial.
doi:10.1371/journal.pone.0252053 pmid:34043677 fatcat:zs5q44hs2ndm5cok6fvk5ggbrm

Effects of β-Adrenergic Antagonists on Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer

Kunal R. Chaudhary, Sherry X. Yan, Samuel P. Heilbroner, Joshua R. Sonett, Mark B. Stoopler, Catherine Shu, Balazs Halmos, Tony J.C. Wang, Tom K. Hei, Simon K. Cheng
2019 Journal of Clinical Medicine  
Locally advanced non-small cell lung cancer (NSCLC) is highly resistant to chemoradiotherapy, and many cancer patients experience chronic stress. Studies that suggest stimulation of β-adrenergic receptors (β-AR) promotes tumor invasion and therapy resistance. We investigated whether β-AR inhibition with beta-blockers acts as a chemotherapy and radiation sensitizer in vitro and in patients treated with chemoradiation for locally advanced NSCLC. Methods: We investigated the effects of the
more » ... ctive beta-blocker propranolol on two human lung adenocarcinoma cell lines (PC9, A549) treated with radiation or cisplatin. We retrospectively evaluated 77 patients with Stage IIIA NSCLC who received induction chemoradiation followed by surgery. Pathological and imaging response, metastatic rate, and survival were analyzed using SPSS v22.0 and PrismGraphpad6. Results: Propranolol combined with radiation or cisplatin decreased clonogenic survival of PC9 and A549 cells in vitro (p < 0.05). Furthermore, propranolol decreased expression of phospho-protein kinase A (p-PKA), a β-adrenergic pathway downstream activation target, in both cell lines compared to irradiation or cisplatin alone (p < 0.05). In patients treated for Stage IIIA NSCLC, 16 took beta-blockers, and 61 did not. Beta-blockade is associated with a trend to improved overall survival (OS) at 1 year (81.3% vs 57.4%, p = 0.08) and distant metastasis-free survival (DMFS) (2.6 years vs. 1.3 years, p = 0.16). Although beta-blocker use was associated with decreased distant metastases (risk ratio (RR) 0.19; p = 0.03), it did not affect primary tumor pathological response (p = 0.40) or imaging response (p = 0.36). Conclusions: β-AR blockade enhanced radiation and cisplatin sensitivity of human lung cancer cells in vitro. Use of beta-blockers is associated with decreased distant metastases and potentially improved OS and DMFS. Additional studies are warranted to evaluate the role of beta-blockers as a chemoradiation sensitizer in locally advanced NSCLC.
doi:10.3390/jcm8050575 pmid:31035526 pmcid:PMC6572477 fatcat:mxn4b2zrdfe37iozq46cmhcr3y

Comparing two LEGO Robotics-based interventions for social skills training with children with ASD

Jordi Albo-Canals, Marcel Heerink, Marta Diaz, Vanesa Padillo, Marta Maristany, Alex Barco, Cecilio Angulo, Ariana Riccio, Lauren Brodsky, Simone Dufresne, Samuel Heilbron, Elissa Milto (+3 others)
2013 2013 IEEE RO-MAN  
This paper presents an analysis of two comparable studies with LEGO Robotics-based activities in a social skills training program for children with autism spectrum disorders (ASD). One study has been carried out with a group of 16 children in the Unit of Pediatrics Psychology and Psychiatry in HSJD in Barcelona , Spain and the other with a group of 17 children at the Center for Education and Engineering Outreach (Tufts U.) in Boston, USA. The aim of this comparison is discuss lessons learnt and
more » ... develop empirical based guidelines for intervention design.
doi:10.1109/roman.2013.6628420 dblp:conf/ro-man/Albo-CanalsHDPMBARBDHMCHR13 fatcat:yisvr44qfbhm3dvsdhmxtdzema

Neoarchean and Rhyacian TTG-Sanukitoid suites in the southern São Francisco Paleocontinent, Brazil: Evidence for diachronous change towards modern tectonics

Henrique Bruno, Vitalino Elizeu, Monica Heilbron, Claudio de Morisson Valeriano, Rob Strachan, Mike Fowler, Samuel Bersan, Hugo Moreira, Ivo Dussin, Luiz Guilherme do Eirado Silva, Miguel Tupinambá, Julio Almeida (+2 others)
2020 Geoscience Frontiers  
Compiled U-Pb data from (a) Heilbron et al., 2010; (b) 1071 Silva et al., 2002; (c) Pinheiro et al., 2019.  ...  Although Archean Nd 663 T DM ages and inherited zircons are documented by Barbosa et al. (2008), Heilbron et al. 664 (2010), and Oliveira et al. (2010), significant juvenile addition took place in the  ... 
doi:10.1016/j.gsf.2020.01.015 fatcat:eupvfsfce5a25jsm2unetknicu

A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity

David J Marchant, Caroline L Bellac, Theo J Moraes, Samuel J Wadsworth, Antoine Dufour, Georgina S Butler, Leanne M Bilawchuk, Reid G Hendry, A Gordon Robertson, Caroline T Cheung, Julie Ng, Lisa Ang (+14 others)
2014 Nature Medicine  
Interferon-a (IFN-a) is essential for antiviral immunity, but in the absence of matrix metalloproteinase-12 or IkBa (encoded by NFKBIA) we show that IFN-a is retained in the cytosol of virus-infected cells and is not secreted. Our findings suggest that activated IkBa mediates the export of IFN-a from virus-infected cells and that the inability of cells in Mmp12 −/− but not wild-type mice to express IkBa and thus export IFN-a makes coxsackievirus type B3 infection lethal and renders respiratory
more » ... yncytial virus more pathogenic. We show here that after macrophage secretion, MMP-12 is transported into virus-infected cells. In HeLa cells MMP-12 is also translocated to the nucleus, where it binds to the NFKBIA promoter, driving transcription. We also identified dual-regulated substrates that are repressed both by MMP-12 binding to the substrate's gene exons and by MMP-12-mediated cleavage of the substrate protein itself. Whereas intracellular MMP-12 mediates NFKBIA transcription, leading to IFN-a secretion and host protection, extracellular MMP-12 cleaves off the IFN-a receptor 2 binding site of systemic IFN-a, preventing an unchecked immune response. Consistent with an unexpected role for MMP-12 in clearing systemic IFN-a, treatment of coxsackievirus type B3-infected wild-type mice with a membrane-impermeable MMP-12 inhibitor elevates systemic IFN-a levels and reduces viral replication in pancreas while sparing intracellular MMP-12. These findings suggest that inhibiting extracellular MMP-12 could be a new avenue for the development of antiviral treatments. npg
doi:10.1038/nm.3508 pmid:24784232 fatcat:tdw3hlcuwjcztbcofslfuzycx4

Page 241 of Guernsey Breeders' Journal Vol. 38, Issue 4 [page]

1930 Guernsey Breeders' Journal  
Heilbron, Media Rose Hill’s Magnolia 291126—Samuel Thompson to Tillie T. Heilbron, Media Rose Hill’s Patricia 2^948—Samuel Thompson to Tillie T.  ...  Holmes Page, Paoli Charter’s Gladys 158309—Samuel Thompson to Tillie T. Heilbron, Media Chrissie of Willow Brook 265560—Samuel Thomp¬ son to Tillie T. Heilbron, Media Cold Water Jewel 310054—Jonas M.  ... 

Page 173 of National Union Catalog Vol. 23, Issue [page]

1963 National Union Catalog  
Quist H3tt 1966 575.1 Heilbronn, Isaac ben Samuel, 18th cent. , joint author see under Heilbronn, Solomon ben Samuel, cent.  ...  Hora'at sha'ah. 1964/65, 18th tHeilbronn, Solomon ben Samuel, /8th cent. we Mune "way MIDIS AMX Fy Aye msn MOM, ...  ... 

Page 3449 of Journal of the Chemical Society Vol. 123-124, Issue 734 [page]

1923 Journal of the Chemical Society  
See Samuel Smiles. Hartshorne, Norman Holt. See Sydney Raymond Carter. Harwood, Frank Courtney, the colloidal electrolyte extracted from carrageen (Chondrus crispus), 2254.  ...  See Isidor Morris Heilbron. Heilbron, Jsidor Morris, Harry Barnes, and Richard Alan Morton, chemical reactivity and conjugation; the re- activity of the 2-methyl group in 2:3-dimethylchromone, 2559.  ... 

M.I. at Kakul

H. Bullock
1937 Notes and Queries  
Originated at 15, Cornhill, in the reign of Geonge I, by Samuel Horton, who took as partner Samuel Birch.  ...  Sreyn, Heilbron, 25 May 1902. J. B. Swartz, Heilbron, 11 June 1902. J. T. Trater, Standerton, 6 Oct. 1902. D. J. De Vittrers, Vrede, 15 June 1902. . J. J. Van Vuren, Wolmaranstad, 18 June 1902. . B.  ... 
doi:10.1093/nq/172.17.296a fatcat:mvthf77xqbhsfjqjhyq23oos3q

An Oversight by Herman Melville

Robert S. Forsythe
1937 Notes and Queries  
Originated at 15, Cornhill, in the reign of Geonge I, by Samuel Horton, who took as partner Samuel Birch.  ...  Sreyn, Heilbron, 25 May 1902. J. B. Swartz, Heilbron, 11 June 1902. J. T. Trater, Standerton, 6 Oct. 1902. D. J. De Vittrers, Vrede, 15 June 1902. . J. J. Van Vuren, Wolmaranstad, 18 June 1902. . B.  ... 
doi:10.1093/nq/172.17.296b fatcat:gbommfrsufauxnytk5d6chcrn4
« Previous Showing results 1 — 15 out of 731 results